Novartis stock plummets 10% after third trial disappointment in a week
FILE PHOTO: The logo of Swiss drugmaker Novartis is seen at the company’s new cell and gene therapy factory in Stein, Switzerland, November 28, 2019. Arnd Wiegmann | Reuters Novartis shares tanked 10% on Tuesday after the pharmaceutical giant said its del-desiran drug for muscle-wasting disorder failed in a late-stage trial. The company’s stock was…
